Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

CALGARY, Alberta , Oct. 19, 2026 (GLOBE NEWSWIRE) — Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug discovery company developing novel therapeutics for autism spectrum disorder (“ASD”) and related neurodevelopmental disorders, is pleased to announce that it has selected CMAX as the […]

We haven't written up this one. Financial Post has the full story — the link below goes straight to it.

Read the original at financialpost.com →

More in Health & Medicine

More from Monday 19 October →